期刊文献+

Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment 被引量:2

下载PDF
导出
摘要 BACKGROUND Sorafenib is an oral drug that prolongs overall survival(OS)in patients with hepatocellular carcinoma.Adverse events,including hand-foot skin reaction(HFSR),lead to permanent sorafenib discontinuation.AIM To clarify the association between interventions for adverse events and patient prognosis.METHODS We performed a retrospective,multicenter study of patients treated with sorafenib monotherapy between May 2009 and March 2018.We developed a mutual cooperation system that was initiated at the start of sorafenib treatment to effectively manage adverse events.The mutual cooperation system entailed patients receiving consultations during which pharmacists provided accurate information about sorafenib to alleviate the fear and anxiety related to adverse events.We stratified the patients into three groups:Group A,patients without HFSR but with pharmacist intervention;Group B,patients with HFSR and pharmacist interventions unreported to oncologists(nonmutual cooperation system);and Group C,patients with HFSR and pharmacist interventions known to oncologists(mutual cooperation system).OS and time to treatment failure(TTF)were evaluated using the Kaplan-Meier method.RESULTS We enrolled 134 patients(Group A,n=41;Group B,n=30;Group C,n=63).The median OS was significantly different between Groups A and C(6.2 vs 13.9 mo,p<0.01)but not between Groups A and B(6.2 vs 7.7 mo,P=0.62).Group A vs Group C was an independent OS predictor(HR,0.41;95%CI:0.25-0.66;P<0.01).In Group B alone,TTF was significantly lower and the nonadherence rate was higher(P<0.01).In addition,the Spearman’s rank correlation coefficients between OS and TTF in each group were 0.41(Group A;P<0.01),0.13(Group B;P=0.51),and 0.58(Group C;P<0.01).There was a highly significant correlation between OS and TTF in Group C.However,there was no correlation between OS and TTF in Group B.CONCLUSION The mutual cooperation system increased treatment duration and improved prognosis in patients with HFSR.Future prospective studies(e.g.,randomized controlled trials)and improved adherence could help prevent OS underestimation.
出处 《World Journal of Gastroenterology》 SCIE CAS 2021年第32期5424-5437,共14页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献2

二级参考文献14

  • 1Xin Zhang, Xin-Rong Yang, Xiao-Wu Huang, Wei-Min Wang, Ruo-Yu Shi, Yang Xu, Zheng Wang, Shuang-Jian Qiu, Jia Fan ,Jian Zhou Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China,Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China.Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review[J].Hepatobiliary & Pancreatic Diseases International,2012,11(5):458-466. 被引量:29
  • 2Masako Shomura,Tatehiro Kagawa,Koichi Shiraishi,Shunji Hirose,Yoshitaka Arase,Tetsuya Mine,Jun Koizumi.Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma[J].World Journal of Hepatology,2014,6(9):670-676. 被引量:6
  • 3Riccardo Lencioni,Josep Llovet.Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma[J]. Semin Liver Dis . 2010 (01)
  • 4Sandra L. Spoelstra,Barbara A. Given,Charles W. Given,Marcia Grant,Alla Sikorskii,Mei You,Veronica Decker.An Intervention to Improve Adherence and Management of Symptoms for Patients Prescribed Oral Chemotherapy Agents: An Exploratory Study[J]. Cancer Nursing . 2013 (1)
  • 5Olive Craven,Carol Anne Hughes,Amy Burton,Mark P. Saunders,Alex Molassiotis.Is a nurse‐led telephone intervention a viable alternative to nurse‐led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer[J]. Eur J Cancer Care (Engl) . 2013 (3)
  • 6Norihiro Kokudo,Junta Nakajima,Etsuro Hatano,Kazushi Numata.Current Status of Hepatocellular Carcinoma Treatment in Japan[J]. Clinical Drug Investigation . 2012 (2)
  • 7Joo Ho Lee,Young‐Hwa Chung,Jeong A. Kim,Ju Hyun Shim,Danbi Lee,Han Chu Lee,Eun‐Soon Shin,Jung Hwan Yoon,Byung Ik Kim,Si Hyun Bae,Kwang Cheol Koh,Neung‐Hwa Park.Genetic predisposition of hand‐foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma[J]. Cancer . 2012 (1)
  • 8R. Lencioni,M. Kudo,S.‐L. Ye,J.‐P. Bronowicki,X.‐P. Chen,L. Dagher,J. Furuse,J. F. Geschwind,L. L. de Guevara,C. Papandreou,A. J. Sanyal,T. Takayama,S. K. Yoon,K. Nakajima,F. Cihon,S. Heldner,J. A. Marrero.First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non‐interventional study[J]. International Journal of Clinical Practice . 2012 (7)
  • 9Toshiya Ochiai,Hisashi Ikoma,Kazuma Okamoto,Yukihito Kokuba,Teruhisa Sonoyama,Eigo Otsuji.Clinicopathologic Features and Risk Factors for Extrahepatic Recurrences of Hepatocellular Carcinoma After Curative Resection[J]. World Journal of Surgery . 2012 (1)
  • 10Barbara A. Given,Sandra L. Spoelstra,Marcia Grant.The Challenges of Oral Agents as Antineoplastic Treatments[J]. Seminars in Oncology Nursing . 2011 (2)

共引文献5

同被引文献8

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部